Evidence map›Paper›PMID 30195795›Full record

ArticleMolecular therapy. Nucleic acids2018

DROSHA Knockout Leads to Enhancement of Viral Titers for Vectors Encoding miRNA-Adapted shRNAs.

Hee Ho Park, Robinson Triboulet, Martin Bentler, Swaroopa Guda, Peng Du, Haiming Xu, Richard I Gregory, Christian Brendel, David A Williams

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Hee Ho ParkDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Program of Biotechnology and Bioengineering, Kangwon National University, Chuncheon, Gangwon-do 24341, Republic of Korea.
Robinson TribouletDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Stem Cell Program, Boston Children's Hospital, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Martin BentlerInstitute of Experimental Hematology, Hannover, Germany.
Swaroopa GudaDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Peng DuDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Stem Cell Program, Boston Children's Hospital, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Haiming XuDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
Richard I GregoryDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Stem Cell Program, Boston Children's Hospital, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA; Harvard Stem Cell Institute, Harvard University, Boston, MA, USA; Harvard Initiative for RNA Medicine, Harvard Medical School, Boston, MA, USA.
Christian BrendelDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Harvard Stem Cell Institute, Harvard University, Boston, MA, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
David A WilliamsDivision of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA; Harvard Stem Cell Institute, Harvard University, Boston, MA, USA; Harvard Initiative for RNA Medicine, Harvard Medical School, Boston, MA, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: dawilliams@childrens.harvard.edu.
Boston Children's Hospital · USHarvard University · USDana-Farber Cancer Institute · USFraunhofer Institute for Toxicology and Experimental Medicine · DE

Funding

Translational and clinical studies targeting y-globin modulationU01HL117720 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI SANKARAN, VIJAY GANESH · 2013 to 2017
$7.4M
Gene therapy targeting BCL11A to induce fetal hemoglobin and reduce sickle hemoglobin in patients with Sickle Cell DiseaseR01HL137848 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI WILLIAMS, DAVID A · 2017 to 2021
$6.0M
NHLBI NIH HHS R01 HL137848NHLBI NIH HHS U01 HL117720
6 · The paper itself

Abstract

RNAi-based gene therapy using miRNA-adapted short hairpin RNAs (shRNA

Indexed as

CRISPR/Cas9DROSHA microprocessorproducer cell linerecombinant viral vector titerRNAi

Identifiers

PMID30195795
PMCPMC6078836
OpenAlexW2873169586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.